Loading…
Loading…
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program
Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totaling 155,110 shares, an increase of 795.6% from the June 30th total of 17,320 shares. Approximately 14.3% of the shares of the stock are sold short. Based
Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate
Silo Pharma Incs (NASDAQ:SILO) announced on Tuesday that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices Inc.'s (NASDAQ:AMD) AI Developer Program, providing access to cloud computing credits, AI development tools, training resources, and a global developer network aimed at accelerating the platform's growth.
SARASOTA, FLA. , July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' AMD AI Developer Program.
Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents
$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash